Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

PRIMARY OBJECTIVES:

• Assess plasma biomarkers for Aβ, GFAP, phospho Tau, and NfL pre- and post-radiotherapy.
• Determine APOE genotype.
• Evaluate neuropsychiatric testing aligned with standard of care brain MRIs and serum markers.
• Measure brain morphometrics pre- and post-radiotherapy with standard of care brain MRIs.

SECONDARY OBJECTIVES:

• Measure patient-reported quality of life changes pre- and post-radiotherapy using a standard University of California, San Francisco (UCSF) -approved questionnaire.

OUTLINE:

This is a single-arm, non-randomized, open-label pilot study. Participants will be study duration spans 12 months post-brain radiotherapy.

Inclusion criteria

• >= 18 years old
• Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
• Diagnosis of primary solid tumor and secondary involvement of the brain
• If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter.
• Candidate for standard of care / usual care (SOC) focused brain radiotherapy.
• No prior brain radiotherapy, including whole brain radiotherapy.
• Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.
• Estimated life expectancy post-treatment of > 2 years.

Exclusion criteria

• Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
• Diagnosis of memory disorder pre-treatment.
• Leptomeningeal disease or disease involving either hippocampus.